{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T17:31:33Z","timestamp":1792949493806,"version":"4.5.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Sarcopenia, the progressive decline of muscle mass and function, has traditionally been viewed as an age-related process leading to a broad range of adverse outcomes. However, it has been widely reported that sarcopenia can occur earlier in life in association with various conditions (i.e. disease-related sarcopenia), including neuromuscular disorders. As early as 2010, the European Working Group on Sarcopenia in Older People included neurodegenerative diseases characterised by motor neuron loss among the mechanisms underlying sarcopenia. Despite some differences in pathogenetic mechanisms, both amyotrophic lateral sclerosis (ALS) and age-related sarcopenia share common characteristics, such as the loss of motor units and muscle fibre atrophy, oxidative stress, mitochondrial dysfunction and inflammation. The histology of older muscle shows fibre size heterogeneity, fibre grouping and a loss of satellite cells, similar to what is observed in ALS patients. Regrettably, the sarcopenic process in ALS patients has been largely overlooked, and literature on the condition in this patient group is very scarce. Some instruments used for the assessment of sarcopenia in older people could also be applied to ALS patients. At this time, there is no approved specific pharmacological treatment to reverse damage to motor neurons or cure ALS, just as there is none for sarcopenia. However, some agents targeting the muscle, like myostatin and mammalian target of rapamycin inhibitors, are under investigation both in the sarcopenia and ALS context. The development of new therapeutic agents targeting the skeletal muscle may indeed be beneficial to both ALS patients and older people with sarcopenia.<\/jats:p>","DOI":"10.1093\/ageing\/afae209","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T11:01:16Z","timestamp":1727089276000},"source":"Crossref","is-referenced-by-count":11,"title":["Amyotrophic lateral sclerosis as a disease model of sarcopenia"],"prefix":"10.1093","volume":"53","author":[{"given":"Domenico","family":"Azzolino","sequence":"first","affiliation":[{"name":"Geriatric Unit, Medical Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano , Milan 20122, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachele","family":"Piras","sequence":"additional","affiliation":[{"name":"Department of Neurological Rehabilitation, Istituti Clinici Scientifici Maugeri IRCCS, Institute of Milan , Milan 20138, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Zulueta","sequence":"additional","affiliation":[{"name":"Department of Neurological Rehabilitation, Istituti Clinici Scientifici Maugeri IRCCS, Institute of Milan , Milan 20138, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Lucchi","sequence":"additional","affiliation":[{"name":"Geriatric Unit, Medical Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano , Milan 20122, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lunetta","sequence":"additional","affiliation":[{"name":"Department of Neurological Rehabilitation, Istituti Clinici Scientifici Maugeri IRCCS, Institute of Milan , Milan 20138, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"key":"2024092311011307300_ref1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"key":"2024092311011307300_ref2","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/ageing\/afq034","article-title":"Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people","volume":"39","author":"Cruz-Jentoft","year":"2010","journal-title":"Age Ageing"},{"key":"2024092311011307300_ref3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJMra1603471","article-title":"Amyotrophic lateral sclerosis","volume":"377","author":"Brown","year":"2017","journal-title":"N Engl J Med"},{"key":"2024092311011307300_ref4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12883-021-02264-y","article-title":"Late-onset neuromuscular disorders in the differential diagnosis of sarcopenia","volume":"21","author":"Hofmeister","year":"2021","journal-title":"BMC Neurol"},{"key":"2024092311011307300_ref5","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S1474-4422(17)30401-5","article-title":"Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications","volume":"17","author":"Chia","year":"2018","journal-title":"Lancet Neurol"},{"key":"2024092311011307300_ref6","first-page":"8","article-title":"Sarcopenia \u2013 endocrinological and neurological aspects","volume":"127","author":"Stangl","year":"2019","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2024092311011307300_ref7","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.clnu.2017.09.003","article-title":"ESPEN guideline clinical nutrition in neurology","volume":"37","author":"Burgos","year":"2018","journal-title":"Clin Nutr"},{"key":"2024092311011307300_ref8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00508-016-1087-5","article-title":"Frailty and sarcopenia in elderly","volume":"128","author":"Morley","year":"2016","journal-title":"Wien Klin Wochenschr"},{"key":"2024092311011307300_ref9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/ggi.13591","article-title":"Sarcopenia and dysphagia: position paper by four professional organizations","volume":"19","author":"Fujishima","year":"2019","journal-title":"Geriatr Gerontol Int"},{"key":"2024092311011307300_ref10","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/000348940811701210","article-title":"Validity and reliability of the Eating Assessment Tool (EAT-10)","volume":"117","author":"Belafsky","year":"2008","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"2024092311011307300_ref11","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/jcsm.12048","article-title":"SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes","volume":"7","author":"Malmstrom","year":"2016","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2024092311011307300_ref12","doi-asserted-by":"crossref","first-page":"S770","DOI":"10.1016\/j.clnesp.2021.09.641","article-title":"Advanced nutritional assessment in patiens with amyotrophic lateral sclerosis","volume":"46","author":"Zarco-Mart\u00edn","year":"2021","journal-title":"Clin Nutr ESPEN"},{"key":"2024092311011307300_ref13","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/ajcn\/77.5.1179","article-title":"Validation of bioelectrical impedance analysis in patients with amyotrophic lateral sclerosis","volume":"77","author":"Desport","year":"2003","journal-title":"Am J Clin Nutr"},{"key":"2024092311011307300_ref14","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1038\/s41467-023-40734-8","article-title":"Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis","volume":"14","author":"Mandrioli","year":"2023","journal-title":"Nat Commun"},{"key":"2024092311011307300_ref15","first-page":"135","article-title":"Challenges in the development of drugs for sarcopenia and frailty \u2013 report from the international conference on frailty and sarcopenia research (ICFSR) task force","volume":"11","author":"Cesari","year":"2022","journal-title":"J Frailty Aging"}],"container-title":["Age and Ageing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ageing\/article-pdf\/53\/9\/afae209\/59237089\/afae209.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ageing\/article-pdf\/53\/9\/afae209\/59237089\/afae209.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T11:01:21Z","timestamp":1727089281000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ageing\/article\/doi\/10.1093\/ageing\/afae209\/7764813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ageing\/afae209","relation":{},"ISSN":["0002-0729","1468-2834"],"issn-type":[{"value":"0002-0729","type":"print"},{"value":"1468-2834","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,9,1]]},"article-number":"afae209"}}